glp-1 agonists reduce inflammation Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation: Cell Metabolism GLP-1 receptor agonists: emerging therapeutic

2 Treatment for type 2 diabetes is initiated based on (glycated hemoglobin) HbA1C levels, treatment goals, and cardiovascular, renal, as well as hypoglycemia risk

In these individuals, the anti-inflammatory effects may provide additional benefit beyond glycemic control

4,6 A key issue in the physiology of type 2 diabetes (T2DM) is the reduced incretin effect, which mainly results from decreased activity of the primary incretin hormones, GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide)

It has also been shown to delay gastric emptying and help suppress appetite

So I called up a co-author of the study, the Washington University physician-scientist Ziyad Al-Aly